Sep 30, 2024 09:25AM
Sep 30, 2024 09:25AM
Sep 23, 2024 08:17AM
Sep 23, 2024 08:17AM
Sep 18, 2024 04:09PM
Sep 18, 2024 04:09PM
Sep 6, 2024 07:56AM Clearmind Medicine (CMND) Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
Sep 6, 2024 07:55AM
Aug 29, 2024 04:26PM
Aug 29, 2024 04:25PM
Aug 29, 2024 04:25PM
Aug 23, 2024 04:09PM
Nov 15, 2023 08:02AM
Nov 15, 2023 08:01AM SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
Nov 15, 2023 08:01AM
Nov 10, 2023 09:10AM
Nov 10, 2023 09:10AM
Jun 2, 2023 09:00AM
Jun 2, 2023 09:00AM
May 2, 2023 07:27AM
May 2, 2023 07:25AM SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
May 2, 2023 07:25AM
Mar 6, 2023 07:45AM
Mar 6, 2023 07:45AM
Mar 6, 2023 07:45AM
Dec 15, 2022 09:00AM
Nov 7, 2022 08:45AM
Nov 7, 2022 08:45AM SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
Nov 7, 2022 08:45AM
Aug 1, 2022 09:30AM
Aug 1, 2022 09:30AM
Aug 1, 2022 09:30AM
Jul 8, 2022 08:32AM
Jul 8, 2022 08:30AM
Jul 8, 2022 08:30AM SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome
Jun 9, 2022 08:35AM
Jun 9, 2022 08:30AM
Jun 9, 2022 08:30AM
Mar 30, 2022 08:30AM
Mar 30, 2022 08:30AM
Jan 18, 2022 08:02AM
Jan 6, 2022 09:00AM SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease

322,897 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All